Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Bilirubin Encephalopathy

Interventions

DRUG: usual prescribed intralipid (UL) regimen
DRUG: restricted prescribed intralipid (RL) regimen

Sponsor

The University of Texas Health Science Center, Houston

Collaborators

[object Object]